Zobrazeno 1 - 10 of 104 pro vyhledávání: '"Gullu Gorgun"'
2
Akademický článek
A community‐based lung cancer rapid tissue donation protocol provides high‐quality drug‐resistant specimens for proteogenomic analyses
Autor: Theresa A. Boyle, Gwendolyn P. Quinn, Matthew B. Schabath, Teresita Muñoz‐Antonia, James J. Saller, Luisa F. Duarte, Laura S. Hair, Jamie K. Teer, Derek Y. Chiang, Rebecca Leary, Connie C. Wong, Alexander Savchenko, Angad P. Singh, LaSalette Charette, Kate Mendell, Gullu Gorgun, Scott J. Antonia, Alberto A. Chiappori, Benjamin C. Creelan, Jhanelle E. Gray, Eric B. Haura
Publikováno v: Cancer Medicine, Vol 9, Iss 1, Pp 225-237 (2020)
Abstract Background For the advancement of cancer research, the collection of tissue specimens from drug‐resistant tumors after targeted therapy is crucial. Although patients with lung cancer are often provided targeted therapy, post‐therapy spec
Externí odkaz: https://doaj.org/article/82ae3eb5e1ff40e2b1ca8ba0ac5ee571
Zobrazit plný text záznamu
3
Akademický článek
Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells.
Autor: Rikio Suzuki, Shohei Kikuchi, Takeshi Harada, Naoya Mimura, Jiro Minami, Hiroto Ohguchi, Yasuhiro Yoshida, Morihiko Sagawa, Gullu Gorgun, Diana Cirstea, Francesca Cottini, Jana Jakubikova, Yu-Tzu Tai, Dharminder Chauhan, Paul G Richardson, Nikhil Munshi, Kiyoshi Ando, Teruhiro Utsugi, Teru Hideshima, Kenneth C Anderson
Publikováno v: PLoS ONE, Vol 10, Iss 12, p e0143847 (2015)
Heat shock protein (HSP)90 inhibitors have shown significant anti-tumor activities in preclinical settings in both solid and hematological tumors. We previously reported that the novel, orally available HSP90α/β inhibitor TAS-116 shows significant
Externí odkaz: https://doaj.org/article/83ce039a22d7489a9099eed0350d4025
Zobrazit plný text záznamu
5
Data from Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma
Autor: Noopur Raje, Kenneth C. Anderson, Sylvie M. Guichard, Francesca Cottini, Rikio Suzuki, Hiroto Ohguchi, Yiguo Hu, Gullu Gorgun, Andrew Yee, Anuj Mahindra, Neeharika Nemani, Yuko Mishima, Homare Eda, Teru Hideshima, Loredana Santo, Diana Cirstea
Despite promising preclinical results with mTOR kinase inhibitors in multiple myeloma, resistance to these drugs may arise via feedback activation loops. This concern is especially true for insulin-like growth factor 1 receptor (IGF1R), because IGF1R
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f1b5cf68b8a926ad1400d49d888efc85
https://doi.org/10.1158/1535-7163.c.6536824.v1
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje